Clearmind Medicine Inc. (CMND) Stock: Jumps Nearly 10% as Phase IIa AUD Trial Begins

TLDR CMND stock jumps 9.92% as Clearmind begins Phase IIa testing of CMND-100 for AUD. Clearmind enrolls six AUD patients as CMND-100 advances into Phase IIa testing. CMND-100 moves into multiple-dose testing after an independent safety review. Clearmind targets alcohol use disorder with its non-hallucinogenic CMND-100 therapy. CMND falls 4.76% pre-market after closing 9.92% higher [...]

The post Clearmind Medicine Inc. (CMND) Stock: Jumps Nearly 10% as Phase IIa AUD Trial Begins appeared first on Blockonomi.